Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.109 extracted from

  • Miyake, Y.; Tsuzuki, S.; Yasumoto, M.; Fushiki, T.; Inouye, K.
    Requirement of the activity of hepatocyte growth factor activator inhibitor type 1 for the extracellular appearance of a transmembrane serine protease matriptase in monkey kidney COS-1 cells (2009), Cytotechnology, 60, 95-103.
No PubMed abstract available
Search for more literature for 3.4.21.109

Cloned(Commentary)

Cloned (Comment) Organism
expresed in COS-1 cells. Wild-type WT-matriptase is detected rarely when expressed alone but co-expression with hepatocyte growth factor activator inhibitor type 1 allowed the detection. Matriptase expression is detected abundantly from the conditioned medium but poorly from a cell membrane-enriched fraction in the co-expression Rattus norvegicus
expressed in COS-1 cells Rattus norvegicus

Inhibitors

Inhibitors Comment Organism Structure
hepatocyte growth factor activator inhibitor type 1 physiological inhibitor of matriptase. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for the extracellular appearance of the protease in an expression system using a monkey kidney COS-1 cell line. In COS-1 cells co-expressing a variant form of HAI-1 without the responsible inhibition domain, matriptase does not appear in the conditioned medium Rattus norvegicus
hepatocyte growth factor activator inhibitor type I hepatocyte growth factor activator inhibitor type I (HAI-1) is shown to be required for the extracellular appearance of matriptase using COS-1 cells. Co-expression of recombinant variants of HAI-1 with the inhibition activity toward matriptase, including a variant consisting only of Kunitz domain I (the domain responsible for inhibition of matriptase), allows for the appearance of matriptase in the conditioned medium, whereas that of the variants without the inhibitory activity does not Rattus norvegicus

Molecular Weight [Da]

Molecular Weight [Da] Molecular Weight Maximum [Da] Comment Organism
28000
-
 SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, activated C-terminal part consiting of the catalytic domain Rattus norvegicus
28000
-
 SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, activated form of matriptase Rattus norvegicus
90000
-
 SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, non-activated C-terminal part Rattus norvegicus
90000
-
 SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, non-activated form of matriptase Rattus norvegicus

Organism

Organism UniProt Comment Textmining
Rattus norvegicus
-
-
-

Posttranslational Modification

Posttranslational Modification Comment Organism
proteolytic modification
-
 Rattus norvegicus
proteolytic modification matriptase is processed post-translationally via cleavage with an unknown intracellular processing enzyme after Gly149 within the SEA domain and that the C-terminal part (Ser150-Val855) is associated with cell membranes via anchoring with the N-terminal part Rattus norvegicus

Synonyms

Synonyms Comment Organism
matriptase
-
 Rattus norvegicus

Expression

Organism Comment Expression
Rattus norvegicus wild-type matriptase is detected rarely when expressed alone in COS-1 cells, but co-expression of hepatocyte growth factor activator inhibitor type I allowed the detection up